Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000650140 | SCV000771977 | uncertain significance | Usher syndrome type 3B | 2024-09-23 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 356 of the HARS protein (p.Ser356Asn). This variant is present in population databases (rs144322728, gnomAD 0.004%). This missense change has been observed in individual(s) with Charcot-Marie-Tooth disease (PMID: 29235198). ClinVar contains an entry for this variant (Variation ID: 446301). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt HARS protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects HARS function (PMID: 29235198). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004023493 | SCV002755226 | uncertain significance | not specified | 2021-11-04 | criteria provided, single submitter | clinical testing | The p.S356N variant (also known as c.1067G>A), located in coding exon 10 of the HARS gene, results from a G to A substitution at nucleotide position 1067. The serine at codon 356 is replaced by asparagine, an amino acid with highly similar properties. This variant was detected in an individual with Charcot-Marie-Tooth disease and in an unaffected parent (Abbott JA et al. Hum Mutat, 2018 03;39:415-432). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV004791505 | SCV005411878 | uncertain significance | not provided | 2024-06-14 | criteria provided, single submitter | clinical testing | PS3 |
Antonellis Laboratory at Michigan, |
RCV000515536 | SCV000611614 | uncertain significance | Autosomal dominant Charcot-Marie-Tooth disease type 2W | no assertion criteria provided | in vitro |